1. Lu, Z., Zou, J., Li, S., Topper, M. J., Tao, Y., Zhang, H., Jiao, X., Xie, W., Kong, X., Vaz, M., Li, H., Cai, Y., Xia, L., Huang, P., Rodgers, K., Lee, B., Riemer, J. B., Day, C. P., Yen, R. C., Cui, Y., Brock, M. V. Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature, 579(7798), 284–290. https://doi.org/10.1038/s41586-020-2054-x

2. Xu J, Shen L, Zhou Z, Li J, Bai C, Chi Y, Li Z, Xu N, Li E, Liu T, Bai Y, Yuan Y, Li X, Wang X, Chen J, Ying J, Yu X, Qin S, Yuan X, Zhang T, Deng Y, Xiu D, Cheng Y, Tao M, Jia R, Wang W, Li J, Fan S, Peng M, Su W. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Nov;21(11):1500-1512. doi: 10.1016/S1470-2045(20)30496-4. Epub 2020 Sep 20. PMID: 32966811.

3. Xu J, Shen L, Bai C, Wang W, Li J, Yu X, Li Z, Li E, Yuan X, Chi Y, Yin Y, Lou W, Xu N, Bai Y, Zhang T, Xiu D, Wang X, Yuan Y, Chen J, Qin S, Jia R, Lu M, Cheng Y, Zhou Z, Li J, He J, Su W. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Nov;21(11):1489-1499. doi: 10.1016/S1470-2045(20)30493-9. Epub 2020 Sep 20. PMID: 32966810.

4. Liu F, Huang C, Xu Z, Su X, Zhao G, Ye J, Du X, Huang H, Hu J, Li G, Yu P, Li Y, Suo J, Zhao N, Zhang W, Li H, He H, Sun Y; Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group. Morbidity and Mortality of Laparoscopic vs Open Total Gastrectomy for Clinical Stage I Gastric Cancer: The CLASS02 Multicenter Randomized Clinical Trial. JAMA Oncol. 2020 Oct 1;6(10):1590-1597. doi: 10.1001/jamaoncol.2020.3152. PMID: 32815991; PMCID: PMC7441466.

5. Cui Y, Chen H, Xi R, Cui H, Zhao Y, Xu E, Yan T, Lu X, Huang F, Kong P, Li Y, Zhu X, Wang J, Zhu W, Wang J, Ma Y, Zhou Y, Guo S, Zhang L, Liu Y, Wang B, Xi Y, Sun R, Yu X, Zhai Y, Wang F, Yang J, Yang B, Cheng C, Liu J, Song B, Li H, Wang Y, Zhang Y, Cheng X, Zhan Q, Li Y, Liu Z. Whole-genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma. Cell Res. 2020 Oct;30(10):902-913. doi: 10.1038/s41422-020-0333-6. Epub 2020 May 12. PMID: 32398863; PMCID: PMC7608103.

6. Dong D, Fang MJ, Tang L, Shan XH, Gao JB, Giganti F, Wang RP, Chen X, Wang XX, Palumbo D, Fu J, Li WC, Li J, Zhong LZ, De Cobelli F, Ji JF, Liu ZY, Tian J. Deep learning radiomic nomogram can predict the number of lymph node metastasis in locally advanced gastric cancer: an international multicenter study. Ann Oncol. 2020 Jul;31(7):912-920. doi: 10.1016 /j.annonc.2020.04.003. Epub 2020 Apr 15. PMID: 32304748.

7. Shenyi Yin, Ruibin Xi, Aiwen Wu, Shu Wang, Yingjie Li, Chaobin Wang, Lei Tang, Yuchao Xia, Di Yang, Juan Li, Buqing Ye, Ying Yu, Junyi Wang, Hanshuo Zhang, Fei Ren, Yuanyuan Zhang, Danhua Shen, Lin Wang, Xiangji Ying, Zhongwu Li, Zhaode Bu, Xin Ji, Xiangyu Gao, Yongning Jia, Ziyu Jia, Nan Li, Ziyu Li, Jia-Fu Ji, Jianzhong Jeff Xi. Patient-derived tumor-like cell clusters for drug testing in cancer therapy. Science Translational Medicine. 2020 Jun 24;12(549)

8. Zhang C, Palashati H, Rong Z, Lin N, Shen L, Liu Y, Li S, Yu B, Yang W, Lu Z. Pre-depletion of TRBC1+ T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies. Mol Cancer. 2020 Nov 21;19(1):162. doi: 10.1186/s12943-020-01282-7. PMID: 33218364; PMCID: PMC7679992.

9. Ma, W., Qiao, J., Zhou, J., Gu, L., & Deng, D. (2020). Characterization of novel LncRNA P14AS as a protector of ANRIL through AUF1 binding in human cells. Mol Cancer, 19(1), 42. https://doi.org/10.1186/s12943-020-01150-4

10. Ma Z, Shuai Y, Gao X, Wen X, Ji J. Circular RNAs in the tumour microenvironment. Mol Cancer. 2020 Jan 14;19(1):8. doi: 10.1186/s12943-019-1113-0. PMID: 31937318; PMCID: PMC6958568.

11. Yang HK, Ji J, Han SU, Terashima M, Li G, Kim HH, Law S, Shabbir A, Song KY, Hyung WJ, Kosai NR, Kono K, Misawa K, Yabusaki H, Kinoshita T, Lau PC, Kim YW, Rao JR, Ng E, Yamada T, Yoshida K, Park DJ, Tai BC, So JBY; EXPEL study group. Extensive peritoneal lavage with saline after curative gastrectomy for gastric cancer (EXPEL): a multicentre randomised controlled trial. Lancet Gastroenterol Hepatol. 2020 Nov 27:S2468-1253(20)30315-0. doi: 10.1016/S2468-1253(20)30315-0. Epub ahead of print. PMID: 33253659.

12. Shan F, Li Z, Ji J. Laparoscopic Gastrectomy After Neoadjuvant Chemotherapy-Reply [published online ahead of print, 2020 Feb 19]. JAMA Surg. 2020;10.1001/jamasurg. 2019.5946. doi:10.1001/jamasurg.2019.5946

13. Chen J, Wang Y, Zhang W, Zhao D, Zhang L, Fan J, Li J, Zhan Q. Membranous NOX5-derived ROS oxidizes and activates local Src to promote malignancy of tumor cells. Signal Transduct Target Ther. 2020 Aug 14;5(1):139. doi: 10.1038/s41392-020-0193-z. PMID: 32792487; PMCID: PMC7426961.

14. Li Z, Gao X, Peng X, May Chen MJ, Li Z, Wei B, Wen X, Wei B, Dong Y, Bu Z, Wu A, Wu Q, Tang L, Li Z, Liu Y, Zhang L, Jia S, Zhang L, Shan F, Zhang J, Wu X, Ji X, Ji K, Wu X, Shi J, Xing X, Wu J, Lv G, Shen L, Ji X, Liang H, Ji J. Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy. Sci Adv. 2020 Feb 26;6(9):eaay4211. doi: 10.1126/sciadv.aay4211. PMID: 32133402; PMCID: PMC7043923.

15. Guan, X., Cai, M., Du, Y., Yang, E., Ji, J., & Wu, J. (2020). CVCDAP: an integrated platform for molecular and clinical analysis of cancer virtual cohorts. Nucleic Acids Res, 48(W1), W463–W471. https://doi.org/10.1093/nar/gkaa423

16. Du Y, Cai M, Xing X, Ji J, Yang E, Wu J. PINA 3.0: mining cancer interactome. Nucleic Acids Res. 2020 Nov 24:gkaa1075. doi: 10.1093/nar/gkaa1075. Epub ahead of print. PMID: 33231689.

17. Zhao S, Zhao H, Lv C, Gong J, Zhang J, Fang W, Li J, Hu X, Ba Y, Xu B, Zhang Y, Fan Y, Li K, Chen X, Yang Z, Shen L, Zhang L. Anticancer drug R&D landscape in China. J Hematol Oncol. 2020 May 13;13(1):51. doi: 10.1186/s13045-020-00877-3. PMID: 32404176; PMCID: PMC7218822.

18. Zhang L, Zhou Y, Cheng C, Cui H, Cheng L, Kong P, Wang J, Li Y, Chen W, Song B, Wang F, Jia Z, Li L, Li Y, Yang B, Liu J, Shi R, Bi Y, Zhang Y, Wang J, Zhao Z, Hu X, Yang J, Li H, Gao Z, Chen G, Huang X, Yang X, Wan S, Chen C, Li B, Tan Y, Chen L, He M, Xie S, Li X, Zhuang X, Wang M, Xia Z, Luo L, Ma J, Dong B, Zhao J, Song Y, Ou Y, Li E, Xu L, Wang J, Xi Y, Li G, Xu E, Liang J, Yang X, Guo J, Chen X, Zhang Y, Li Q, Liu L, Li Y, Zhang X, Yang H, Lin D, Cheng X, Guo Y, Wang J, Zhan Q, Cui Y. Genomic Analyses Reveal Mutational Signatures and Frequently Altered Genes in Esophageal Squamous Cell Carcinoma. Am J Hum Genet. 2020 Aug 6;107(2):375. doi: 10.1016/j.ajhg.2020.07.008. Erratum for: Am J Hum Genet. 2015 Apr 2;96(4):597-611. PMID: 32763191; PMCID: PMC7413884.

19. Dengbo Ji, Can Song, Yongheng Li, Jinhong Xia, Yanjing Wu, Jinying Jia,Xinxin Cui, Songmao Yu, Jin Gu. Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer. J Immunother Cancer. 2020 Oct;8(2)

20. Wang Z, Zhao X, Gao C, Gong J, Wang X, Gao J, Li Z, Wang J, Yang B, Wang L, Zhang B, Zhou Y, Wang D, Li X, Bai Y, Li J, Shen L. Plasma-based microsatellite instability detection strategy to guide immune checkpoint blockade treatment. J Immunother Cancer. 2020 Nov;8(2):e001297. doi: 10.1136/jitc-2020-001297. PMID: 33172882; PMCID: PMC7656957.

21. Lu Z, Chen H, Jiao X, Zhou W, Han W, Li S, Liu C, Gong J, Li J, Zhang X, Wang X, Peng Z, Qi C, Wang Z, Li Y, Li J, Li Y, Brock M, Zhang H, Shen L. Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier. J Immunother Cancer. 2020 Aug;8(2):e000631. doi: 10.1136/jitc-2020-000631. PMID: 32792359; PMCID: PMC7430448.

22. Lu Z, Chen H, Li S, Gong J, Li J, Zou J, Wu L, Yu J, Han W, Sun H, Jiao X, Zhang X, Peng Z, Lu M, Wang Z, Zhang H, Shen L. Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer. J Immunother Cancer. 2020 Aug;8(2): e000374. doi: 10.1136/jitc-2019-000374. PMID: 32792358; PMCID: PMC7430454.

23. Shen L, Guo J, Zhang Q, Pan H, Yuan Y, Bai Y, Liu T, Zhou Q, Zhao J, Shu Y, Huang X, Wang S, Wang J, Zhou A, Ye D, Sun T, Gao Y, Yang S, Wang Z, Li J, Wu YL. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. J Immunother Cancer. 2020 Jun;8(1):e000437. doi: 10.1136/jitc-2019-000437. Erratum in: J Immunother Cancer. 2020 Jul;8(2): PMID: 32561638; PMCID: PMC7304812.

24. Wang YY, Xiang BD, Ma L, Zhong JH, Ye JZ, Wang K, Xing BC, Li LQ. Development and Validation of a Nomogram to Preoperatively Estimate Post-hepatectomy Liver Dysfunction Risk and Long-term Survival in Patients With Hepatocellular Carcinoma. Ann Surg. 2020 Feb 24. doi: 10.1097/SLA.0000000000003803. Epub ahead of print. PMID: 32097166.

25. Liu H, Lei W, Zhang C, Yang C, Wei J, Guo Q, Guo X, Chen Z, Lu Y, Young KH, Lu Z, Qian W. CD19-Specific CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma. Clin Cancer Res. 2020 Oct 7:clincanres.1457.2020. doi: 10.1158/1078-0432.CCR-20-1457. Epub ahead of print. PMID: 33028589.

26. Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, Zhang H, Ji J, Xu W, Jin J, Lv F, Feng R, Gao S, Guo H, Zhou L, Elstrom R, Huang J, Novotny W, Wei R, Zhu J. Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. Clin Cancer Res. 2020 Aug 15;26(16):4216-4224. doi: 10.1158/1078-0432.CCR-19-3703. Epub 2020 May 27. PMID: 32461234.

27. Sheng X, Yan X, Wang L, Shi YX, Yao X, Luo H, Shi B, Liu JY, He Z, Yu G, Ying J, Han W, Hu CL, Ling Y, Chi Z, Cui C, Si L, Fang J, Zhou A, Guo J. Open-label, multicenter, phase 2 study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin Cancer Res. 2020 Oct 27:clincanres.2488.2020. doi: 10.1158/1078-0432.CCR-20-2488. Epub ahead of print. PMID: 33109737.

28. Lu M, Zhang P, Zhang Y, Li Z, Gong J, Li J, Li J, Li Y, Zhang X, Lu Z, Wang X, Zhou J, Peng Z, Wang W, Feng H, Wu H, Yao S, Shen L. Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial. Clin Cancer Res. 2020 May 15;26(10):2337-2345. doi: 10.1158/1078-0432.CCR-19-4000. Epub 2020 Feb 21. PMID: 32086343.

29. Tang, B., Chi, Z., Chen, Y., Liu, X., Wu, D., Chen, J., Song, X., Wang, W., Dong, L., Song, H., Wu, H., Feng, H., Yao, S., Qin, S., Zhang, X., & Guo, J. (2020). Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial. Clin Cancer Res : an official journal of the American Association for Cancer Research, 26(16), 4250–4259. https://doi.org/10.1158/1078-0432.CCR-19-3922